Biological Therapy in Noninfectious Pediatric Uveitis: A Systematic Review

References

• Gamalero L, Simonini G, Ferrara G, Polizzi S, Giani T, Cimaz R. Evidence-based treatment for uveitis. Isr Med Assoc J. 2019;21(7):475–479.
   PubMed Web of Science ®Google Scholar
• Siiskonen M, Hirn I, Pesälä R, Hautala T, Ohtonen P, Hautala N. Prevalence, incidence and epidemiology of childhood uveitis. Acta Ophthalmol. 2021;99(2):e160–e163. doi:10.1111/aos.14535
   PubMed Web of Science ®Google Scholar
• Chan NS, Choi J, Cheung CMG. Pediatric Uveitis. Asia Pac J Ophthalmol. 2018;7(3):192–199.
   PubMed Web of Science ®Google Scholar
• Thurau S. Childhood Uveitis. Klin Monbl Augenheilkd. 2020;237(10):1177–1186. doi:10.1055/a-1252-5281.
   Google Scholar
• Cann M, Ramanan AV, Crawford A, et al. Outcomes of noninfectious Paediatric uveitis in the era of biologic therapy. Pediatr Rheumatol Online J. 2018;16(1):51. doi:10.1186/s12969-018-0266-5
   PubMed Web of Science ®Google Scholar
• Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile Idiopathic Arthritis. Med J. 2017;34(2):90–101.
   Google Scholar
• Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019;30(3):138–150. doi:10.1097/ICU.0000000000000562
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Ninhes T, Schumacher C, et al. Diagnostik und antientzündliche Therapie der Uveitis bei juveniler idiopathischer Arthritis. In: Wirth S, Creutzig R, Krauspe R, Lehrnbecher T, Mentzel HJ, Niehues T, editors. Leitlinien Kinder- und Jugendmedizin. Urban & Fischer; 2015. H8.1–H8.17.
   Google Scholar
• Phatak S, Agrawal R, Pavesio C. Adalimumab: viable treatment option for pediatric refractory uveitis? Expert Rev Ophthalmol. 2014;9(3):175–184. doi:10.1586/17469899.2014.903801
   Google Scholar
• Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS. 2008;12(6):611–613. doi:10.1016/j.jaapos.2008.08.007
   PubMed Web of Science ®Google Scholar
• Hu Y, Huang Z, Yang S, Chen X, Su W, Liang D. Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: a Systematic Review and Meta-Analysis. Front Pharmacol. 2020;11:941. doi:10.3389/fphar.2020.00941
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2th ed. Chichester (UK): John Wiley & Sons; 2019.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi:10.1136/bmj.39489.470347.AD
   PubMed Web of Science ®Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394. doi:10.1016/j.jclinepi.2010.04.026
   PubMed Web of Science ®Google Scholar
• McMaster University. GRADEpro GDT: gRADEpro Guideline Development Tool [Software] [Internet]. Evidence Prime, Inc.; 2015. Available from: https://gradepro.org. Accessed August 30, 2021.
   Google Scholar
• The Cochrane Collaboration. Review Manager (Revman). Copenhagen: The Nordic Cochrane Centre; 2015.
   Google Scholar
• Smith JA, Thompson DJS, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18–23. doi:10.1002/art.20904
   PubMed Web of Science ®Google Scholar
• Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early-onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2017;77:1–9.
   Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637–1646. doi:10.1056/NEJMoa1614160
   PubMed Web of Science ®Google Scholar
• Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(4):548–550. doi:10.1136/ard.2006.058248
   PubMed Web of Science ®Google Scholar
• Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res. 2011;63:612–618. doi:10.1002/acr.20404
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow-up data from the Italian Registry. J Rheumatol. 2013;40(1):74–79. doi:10.3899/jrheum.120583
   PubMed Web of Science ®Google Scholar
• Gaidar EV, Kostik MM, Snegireva LS, et al. Outcomes of treatment of juvenile idiopathic arthritis related uveitis with TNF-alpha inhibitors. Pediatrician. 2014;5:60–64.
   Google Scholar
• Cecchin V, Zannin ME, Ferrari D, et al. Long-term Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2018;45(8):1167–1172. doi:10.3899/jrheum.171006
   PubMed Web of Science ®Google Scholar
• Gunduz GU, Yalcinbayir O, Cekic S, Yildiz M, Kilic SS. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: infliximab Versus Adalimumab. J Ocul Pharmacol Ther. 2021;37:1–5.
   Web of Science ®Google Scholar
• Schnabel A, Unger E, Brück N, et al. High-dose intravenous methylprednisolone in juvenile noninfectious uveitis: a retrospective analysis. Clin Immunol. 2019;211:108327. doi:10.1016/j.clim.2019.108327
   Web of Science ®Google Scholar
• Gallego-Pinazo R, Dolz-Marco R, Martínez-Castillo S, Arévalo JF, Díaz-Llopis M. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets. 2013;12(1):38–45. doi:10.2174/1871528111312010006
   PubMedGoogle Scholar
• Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007;17(5):743–748. doi:10.1177/112067210701700509
   PubMed Web of Science ®Google Scholar
• Hughes DA, Culeddu G, Plumpton CO, et al. Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis. Ophthalmology. 2019;126(3):415–424. doi:10.1016/j.ophtha.2018.09.043
   PubMed Web of Science ®Google Scholar
• Lightman S, Niederer R, Sharma S, et al. Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis. Ophthalmology. 2019;126(3):e22–e24. doi:10.1016/j.ophtha.2018.12.004
   Web of Science ®Google Scholar
• Symes RJ, Zagora SL, Younan C, et al. Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis. Ophthalmology. 2019;126(10):e77. doi:10.1016/j.ophtha.2019.04.039
   Google Scholar
• Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current Evidence of Anti–Tumor Necrosis Factor α Treatment Efficacy in Childhood Chronic Uveitis: a Systematic Review and Meta-Analysis Approach of Individual Drugs. Arthritis Care Res (Hoboken). 2014;66(7):1073–1084. doi:10.1002/acr.22214
   PubMed Web of Science ®Google Scholar